Ototoxic hearing loss in the multi-drug resistant tuberculosis era (original) (raw)
Related papers
2013
Until now, examination of hearing loss degree in patients with MDRTB who received TB treatment has not been done. It is importantto prevent the effects of TB drugs against hearing loss or deafness. The results of the study on center TB hospitals at Beatrixoord inJanuary 1995 through July 2000 showed the prevalence of hearing loss due to ototoxic was quite large, 41%. This study is aretrospective descriptive study to obtain the incidence of hearing loss in MDRTB patients were performed at pulmonary division Dr.Soetomo Hospital Surabaya. The data was taken from patients visited from 1 January2009 through 31 December 2011. In general,there were 41 MDRTB patients with age range 22-60 years old. Mainly, patients were in the age group 31-40 years old(36.6%).Mostly they were treatment failure patients, 18 people(44%), relapsed patients as many as 13 people(31.6%), and inattentive 10people24.4%). From the anamnesis, hearing complaints obtained at 19 people(46.3%), and 22 people(53.7%) did n...
2017
Background: Multidrug-resistant tuberculosis (MDR-TB) is an increasing challenge to health services globally. Although new drugs are in development, current guidelines still recommend prolonged use of injectable antimicrobials (usually Amikacin, Kanamycin or Capreomycin). Methods: We conducted a retrospective study of patients initiating treatment for MDR-TB at Programmatic Management of Drug Resistant TB unit, Lady Reading Hospital (PMDT-LRH) Peshawar between January 2012 and December 2013. Objective: Objective of the present study is to find out the incidence of ototoxicity (defined both clinically and on audiological testing), its associated factors and its effects on final outcome. Results: The choice of injectable antimicrobial varied. Total of 543 patients treated with injectable antimicrobials for MDR-TB were included in the analysis. Of 543 MDR-TB patients, 476 (87.7%) received amikacin and 67 (12%) received capreomycin. All the patients received baseline screening by audiom...
Hearing loss among patients on treatment for drug-resistant tuberculosis in Uganda
South Sudan Medical Journal, 2021
Introduction: Second-line injectable therapy using aminoglycosides (AG) like kanamycin, amikacin or capreomycin is associated with irreversible hearing loss. We aimed to determine the incidence and predictors of hearing loss among patients with drug resistant tuberculosis (DR-TB) who received AG.Method: This was a retrospective cohort study conducted at the tuberculosis treatment unit of Mbarara Regional Referral Hospital (MRRH). All adult patients with a diagnosis of DR-TB between March 2016 and December 2019 were candidates for inclusion in the study. Hearing loss was defined as a hearing threshold of >20 decibels (dB) at any test frequency in at least one ear. The incidence and predictors of hearing loss were analysed using multivariable Cox model. A p-value of ≤0.05 was considered as statistically significant. Data analysis was done using STATA version 13.Results: The estimated rate of developing hearing loss was 107 per 1000 person months. Thirty-seven (52.9%) of 70 DR-TB pa...
JMIR mHealth and uHealth, 2020
Background Tuberculosis (TB) affects millions of people worldwide and is treated with medication including aminoglycosides and polypeptides. Individuals respond differently to medications as a result of their genetic inheritance. These differences in genetic inheritance can result in the underdosing or overdosing of medication, which may affect the efficacy or, in the case of aminoglycosides and polypeptides used in the treatment of all forms of TB, result in ototoxicity. When ototoxicity is detected, physicians should adjust dosages to minimize further ototoxicity and hearing loss; however, there are no suitable grading systems to define significant hearing loss. Objective The aim of this study was to develop a standardized grading system by making use of an electronic health (eHealth) platform to ensure that a user-friendly method was available to interpret hearing test results, calculate significant hearing loss, and provide recommendations with regard to dosage adjustments and m...